Shalby Limited Reports Q4 FY2026 Financial Results

Shalby Limited announced its financial results for the quarter and fiscal year ending March 31, 2026. The company posted a consolidated profit of ₹18.45 crore for the fourth quarter and ₹34.69 crore for the full fiscal year. On a standalone basis, the profit for the quarter was ₹53.67 crore, and for the year, it reached ₹112.91 crore.

Key Financials Announced

The company's consolidated revenue from operations was ₹287.45 crore for the quarter and ₹1,141.43 crore for the full year. These figures reflect the company's overall financial performance for the period.

Factors Affecting Quarterly Profit

Shalby's quarterly profit was significantly impacted by a one-time tax adjustment of ₹34.02 crore. This adjustment resulted from the company's decision to adopt the lower tax regime available under Section 115BAA. Additionally, a write-off of ₹4.24 crore for MAT credit and an impairment charge of ₹0.70 crore on its investment in subsidiary Yogeshwar Healthcare Limited were recognized. The impairment reduced the carrying value of the investment in Yogeshwar Healthcare to zero.

Segment Performance Overview

For the fiscal year 2026, Shalby's Healthcare Services segment was a strong performer, generating ₹1,010.14 crore in revenue and a profit of ₹95.28 crore. In contrast, the Manufacturing & Trading of Implants segment reported revenue of ₹131.29 crore but incurred a loss of ₹34.72 crore, though this loss has shown a reduction.

Future Implications

The adoption of the new tax regime is expected to influence future tax liabilities. The impairment charge has directly reduced the reported quarterly profit. The company also decided against recommending a dividend for FY 2025-26, indicating a focus on retaining capital for operational needs.

Areas of Concern

The ongoing losses within the Manufacturing & Trading of Implants segment present a challenge. Investors will closely watch Shalby's strategies to improve profitability in this specific area.

Key Metrics for FY 2026

• Consolidated Revenue: ₹1,141.43 crore
• Consolidated Profit: ₹34.69 crore
• Standalone Profit: ₹112.91 crore
• One-time tax impact: ₹34.02 crore
• Subsidiary impairment: ₹0.70 crore

Investor Focus Areas

Moving forward, investors are likely to monitor the performance of the robust Healthcare Services segment. Additionally, strategies to address the profitability challenges in the Manufacturing & Trading of Implants segment, along with the long-term impact of the new tax regime, will be key points of interest.